Glaukos, which sells micro-scale surgical devices for treating glaucoma, announced terms for its IPO on Monday. The Laguna Hills, CA-based company plans to raise $75 million by offering 5.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Glaukos would command a fully diluted market value of $474 million.
Glaukos, which was founded in 1998 and booked $52 million in sales for the 12 months ended March 31, 2015, plans to list on the NYSE under the symbol GKOS. Glaukos initially filed confidentially on 7/23/2014. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs are the joint bookrunners on the deal. It is expected to price during the week of June 22, 2015.
